DRDhivyaa Rajasundaram

Dhivyaa Rajasundaram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dhivyaa Rajasundaram has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genome-Wide Transcriptomics Uncovers a Lung-to-Aorta Inflammatory Program Driving Influenza-Induced Atherosclerosis Exacerbation

    by Louis DeVito, John C. Notaro, Nicholas J. Constantinesco, Dhivyaa Rajasundaram, John F. Alcorn, Radha Gopal

    SUMMARY: Influenza infection increases cardiovascular risk in individuals with pre-existing atherosclerosis, yet the genome-wide transcriptional basis of this association remains undefined. We performed bulk RNA sequencing of aorta and lung tissues from high-fat diet-fed Apoe −/− mice infected with influenza A/PR/8/34 versus PBS-treated controls at day 15 post-infection, identifying 6,828 differentially expressed genes across both tissues (5,694 in the lung and 1,134 in the aorta; adjusted p < 0.05). In the lung, influenza sustained a CXCR3-driven chemokine storm, comprehensive Th1, Th17, and exhaustion T-cell activation programs, coordinated monocyte recruitment through Ccl2 , Ccl7 , Ccl8 , and Ccl12 , a broad acute phase response including Saa3 and A2m , alveolar identity collapse through loss of Nkx2-1 and surfactant proteins, and broad metabolic dysregulation involving suppression of fatty acid oxidation, mitochondrial function, and circadian metabolic regulators. In the aorta, influenza drove macrophage and DAMP activation through Trem1 , Fpr2 , and S100a8 , cytotoxic T-cell engagement, smooth muscle cell dedifferentiation through Myocd loss, convergent bioenergetic failure, and an ectopic lung-identity gene signature representing a previously undescribed cross-organ communication mechanism. Circadian clock and Hippo/YAP pathway suppression were shared across both tissues, identifying systemic vulnerabilities connecting pulmonary infection to vascular structural compromise. Consistent with the in vivo findings, influenza-infected Apoe −/− bone marrow-derived macrophages exhibited inflammasome activation, DAMP amplification, M1 polarization, and suppression of prostaglandin-mediated inflammatory resolution. Together these findings define a lung-to-aorta inflammatory and metabolic axis driving atherosclerotic plaque destabilization during the post-infection recovery period and identify CCR2/CXCR3 antagonism, NLRP3 inhibition, and YAP pathway activation as candidate therapeutic interventions. Graphical Influenza infection drives atherosclerotic plaque destabilization

  • Open Access

    Figure 4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    The gut microbiota is necessary and sufficient to drive immunotherapy resistance due to sucralose. A, Mice consumed sucralose (0.09 mg/mL) in the drinking water for 14 days prior to antibiotic treatment and for the duration of the experiment. After 21 days of sucralose supplementation with or without antibiotics, mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with anti–PD-1 on days 9, 12, and 15. B, Tumor growth curve and overall survival plot of experiment described in A. CR, complete response. C, FMT experimental overview. Donor mice (red) were given sucralose-supplemented drinking water (0.09 mg/mL) for 2 weeks prior to donating stool. Stool was transferred to sucralose-naïve recipient mice (light pink) that had received broad-spectrum antibiotics for 7 days prior to transfer. Tumors were injected as previously described in 4A and measured until endpoint. D, Tumor growth curve of the experiment described in C. Data are a composite of three (B and C) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. Two-way ANOVA (B and D) was used. *, P < 0.05.

  • Open Access

    Figure 5 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Responder-derived FMT is sufficient to restore immunotherapeutic response. A, Individual tumor growth curves from Fig. 4D with FMT. B and C, C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. Four groups all received an FMT from an anti–PD-1 responder mouse donor. The following four groups were used: antibiotic treatment pre-FMT, continued sucralose consumption (hot pink), antibiotic treatment pre-FMT, stopped sucralose consumption (light pink), no antibiotics, continued sucralose consumption (purple), no antibiotics, stopped sucralose consumption (light blue). Individual tumor growth curves (B) and a composite growth curve and OS (C) are shown. Data are a composite of three (A) or two (B and C) independent experiments with five mice per group per replicate. Error bars represent the mean ± SEM. For growth curve statistics, two-way ANOVA was used. OS statistics were calculated using a log-rank Mantel–Cox test. *, P < 0.05. abx, antibiotics; CR, complete response.

  • Open Access

    Appendix 1 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Appendix 1 shows the IRB approval for HCC 20-019.

  • Open Access

    Supplementary Fig S11 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Supplementary Fig S11 shows a volcano plot and pathway enrichment of T cells cultured in sucralose during activation and expansion.

  • Open Access

    Supplementary Tables S1-4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Supplementary Tables S1-4 show univariate and multivariate analysis of patient data.

  • Open Access

    Supplementary Fig S9 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Supplementary Fig S9 shows T cell proliferation and metabolism following sucralose culture during activation, expansion, or the entirety of culture.

  • Open Access

    Supplementary Fig S3 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Supplementary Fig S3 shows overall response rate and progression free response rate for patients consuming aspartame or saccharin.

  • Open Access

    Figure 2 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Sucralose ablates immunotherapeutic responses. C57BL/6 mice from Taconic consumed sucralose in the drinking water (0.09 mg/mL) for 2 weeks prior to tumor injection and for the duration of the experiment. Mice were injected with 2.5 × 105 MC38 cells subcutaneously and treated with 200 µg anti–PD-1 on days 9, 12, and 15. Tumor area was measured every 3 days until endpoint. A, Experimental schematic. B, Tumor growth curves of mice consuming sucrose or sucralose in the drinking water during treatment with anti–PD-1. CR, complete response. C, Tumor growth curves in MC38 subcutaneous (circles) or B16 intradermal (squares) treated with anti–PD-1. Mice were sourced from either The Jackson Laboratory (Jax, open circles) or Taconic Biosciences (Taconic, closed circles). Mice were removed from study either when tumors reached 2 cm in either direction or if there was unresolved ulceration. Mean tumor growth lines halt once all mice in a treatment group were removed. D and E, C57BL/6 mice from either Taconic (D) or Jackson (E) consumed sucralose in their drinking water as in (C). They were subjected to the AOM-DSS protocol (injected with 10 mg/kg AOM on day 0 and given 3% DSS in the drinking water on days 7–14 and 28–35). Overall tumor number and composition of “large” tumors (>2 mm in any direction) are shown. Data are a composite of three (C) or two (B and D) independent experiments with five mice per group per experiment. Error bars represent the mean ± SEM. A two-way ANOVA (C) or Student t test (D) was used. *, P < 0.05; ns, not significant.

  • Open Access

    Supplementary Fig S4 from Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    by Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi Dahmani, Ansen B.P. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, et al.

    Supplementary Fig S4 shows the individual tumor growth curves from mice consuming artificial sweeteners, overall survival, and tumor area. It also shows tumor growth curves for mice that were cohoused.